- Home
- CDIO vs TRAW Comparison
CDIO vs TRAW Comparison
Compare CDIO & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- TRAW
- Stock Information
- Founded
- CDIO 2017
- TRAW 1998
- Country
- CDIO United States
- TRAW United States
- Employees
- CDIO N/A
- TRAW N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- TRAW
- Sector
- CDIO Health Care
- TRAW
- Exchange
- CDIO Nasdaq
- TRAW NYSE
- Market Cap
- CDIO 7.0M
- TRAW 7.8M
- IPO Year
- CDIO N/A
- TRAW 2013
- Fundamental
- Price
- CDIO $4.77
- TRAW $1.65
- Analyst Decision
- CDIO Buy
- TRAW
- Analyst Count
- CDIO 1
- TRAW 0
- Target Price
- CDIO $60.00
- TRAW N/A
- AVG Volume (30 Days)
- CDIO 102.5K
- TRAW 3.5M
- Earning Date
- CDIO 05-15-2025
- TRAW 05-15-2025
- Dividend Yield
- CDIO N/A
- TRAW N/A
- EPS Growth
- CDIO N/A
- TRAW N/A
- EPS
- CDIO N/A
- TRAW N/A
- Revenue
- CDIO $19,902.00
- TRAW $227,000.00
- Revenue This Year
- CDIO $1,434.82
- TRAW $3.81
- Revenue Next Year
- CDIO $4,661.91
- TRAW $30.43
- P/E Ratio
- CDIO N/A
- TRAW N/A
- Revenue Growth
- CDIO N/A
- TRAW 0.44
- 52 Week Low
- CDIO $3.40
- TRAW $0.97
- 52 Week High
- CDIO $53.10
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- CDIO 39.92
- TRAW 54.15
- Support Level
- CDIO $3.88
- TRAW $1.30
- Resistance Level
- CDIO $5.20
- TRAW $2.58
- Average True Range (ATR)
- CDIO 0.48
- TRAW 0.23
- MACD
- CDIO 0.32
- TRAW 0.07
- Stochastic Oscillator
- CDIO 68.25
- TRAW 34.04
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.